Published in Health Business Week, January 14th, 2005
Creation Capital, LLC, served as the sole placement agent for the offering. With the completion of the Series B financing, Amedica has a total of approximately 27 million shares outstanding and management believes the company is sufficiently capitalized to execute its plans well into 2007.
Amedica plans to use the proceeds of this transaction to continue advancing product development including its clinical trials, to complete and validate its manufacturing capabilities, to hire additional key personnel, to launch certain...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.